Metagenomi, Inc. (MGX)
(Delayed Data from NSDQ)
$4.08 USD
+0.31 (8.22%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $4.13 +0.05 (1.23%) 7:58 PM ET
D Value D Growth D Momentum F VGM
Metagenomi (MGX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.83 | $25.00 | $6.00 | 346.42% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Metagenomi comes to $16.83. The forecasts range from a low of $6.00 to a high of $25.00. The average price target represents an increase of 346.42% from the last closing price of $3.77.
Analyst Price Targets (6 )
Broker Rating
Metagenomi currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MGX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.33 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/7/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/5/2024 | BMO Capital Markets | Kostas Biliouris | Not Available | Strong Buy |
3/5/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/5/2024 | Chardan Capital Markets | Geulah Livshits | Not Available | Strong Buy |
3/5/2024 | Wells Fargo Securities | Yanan Zhu | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 7 |
Average Target Price | $16.83 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | -0.59 |